ICPT
ICPT Articles
Thursday's top analyst upgrades, downgrades and initiations include Alibaba, Mobileye, NetApp, Nike, Salesforce.com and Stratasys.
Published:
Investors are not too happy with Intercept Pharmaceuticals after it released the terms for its most recent clinical trial.
Published:
247 Wall St. could not help but notice four analyst calls this past week in which upside of 50% to 100% was predicted for four biotech and specialty pharma stocks.
Published:
Friday's top analyst upgrades, downgrades and initiations include Apple, CyberArk, EMC, Goldman Sachs, SanDisk, ULTA Beauty and Wayfair.
Published:
As we approach the earnings releases for the first quarter, we are seeing an increase in the insider selling activity.
Published:
We have seen an increase in insider selling since the end of the fourth-quarter earnings reporting season, so this past week's action can hardly be described as panicked.
Published:
One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech companies could have some very import clinical data releases.
Published:
Insider selling takes many different forms, but investors may want to see if any of these names reside in their portfolios and need to be trimmed.
Published:
Jon OggStocks were holding on to small gains on Tuesday even after weaker sentiment was reported out of Europe. It looks as though investors have decided they can now shop around for stocks that have...
Published:
Thinkstock24/7 Wall St. has tracked several key stocks on the move in Monday’s after-hours trading session. There are other stocks on the move, but these were the top movers that we saw. Some of...
Published:
We have seen four biotech research reports in which the analysts covering these stocks are now calling for upside of 100% -- or even higher!
Published:
ThinkstockA brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The...
Published:
ThinkstockInvestors and speculators often flock to the world biotech for emerging drugs of the future. It is no secret at all that the biotech sector is full of all sorts of risks, making and taking...
Published:
ThinkstockBinary events are often the key element in moving a biotech or health care stock higher. Negative binary results or actions often can move shares drastically lower. We scan our 24/7 Wall...
Published:
A new report from the analysts at Cowen shows that, on average, biotech stocks gained 84% in the 12 months prior to an FDA approval and lost 24% in the 12 months after the approval.
Published: